• Journal Article

Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass

Citation

Kendler, D. L., Bessette, L., Hill, C. D., Gold, D. T., Horne, R., Varon, S. F., ... Bone, H. G. (2010). Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporosis International, 21(5), 837-846.

Abstract

The Preference and Satisfaction Questionnaire (PSQ) compares patient preference and satisfaction between a 6-month subcutaneous injection and weekly oral tablet for treatment of bone loss. Patients preferred and were more satisfied with a treatment that was administered less frequently, suggesting the acceptability of the 6-month injection for treatment of bone loss.
The PSQ compares patient preference and satisfaction between a 6-month subcutaneous injection and a weekly oral tablet for treatment of bone loss.

Postmenopausal women with low bone mass who enrolled in two separate randomized phase 3 double-blind, double-dummy studies received a 6-month subcutaneous denosumab injection (60 mg) plus a weekly oral placebo or a weekly alendronate tablet (70 mg) plus a 6-month subcutaneous placebo injection. After 12 months, patients completed the PSQ to rate their preference, satisfaction, and degree of bother with each regimen.

Most enrolled patients (1,583 out of 1,693; 93.5%) answered a parts per thousand yen1 item of the PSQ. Significantly more patients preferred and were more satisfied with the 6-month injection versus the weekly tablet (P < 0.001). More patients reported no bother with the 6-month injection (90%) than the weekly tablet (62%).

Patients preferred, were more satisfied, and less bothered with a 6-month injection regimen for osteoporosis.